Press Enter to search · ESC to close

Crypto Macro

Grand Pharma’s Y-90 Microsphere Product Added to China Commercial Insurance Drug List

Grand Pharma’s key nuclear medicine product Yigan Tai (yttrium-90 microsphere injection) was selected for the first time into China’s Commercial Health Insurance Innovative Drug Catalog (2026), issued by the National Healthcare Security Administration, and also into the first edition of the Commercial Health Insurance Drug Recommendation List released by the Insurance Association of China. It is the only selective internal radiation therapy (SIRT) product included in the commercial insurance innovative drug catalog this time.

Share

Related News

Cointime share card
Long-press the image to save or share
Pitch us Community Feedback